Overview

Mirabegron For Erectile Dysfunction

Status:
Completed

Trial end date:
2020-01-01

Target enrollment:

Participant gender:

Summary

The only class of oral erectile dysfunction (ED) medication on the market are the phosphodiesterase Type 5 inhibitors (PDE5i). This pilot study is being done to evaluate the effect of Mirabegron, an oral beta-3 adrenergic agonist, on men with both Overactive Bladder (OAB) symptoms and mild to moderate ED.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

Astellas Pharma US, Inc.

Treatments:

Mirabegron